Patent · US Active

G-CSF conjugates

US7696153B2 · kind B2 · utility

15Cited by

75References

8Claims

0Family size

Assignee

Maxygen, Inc. · US

Inventors

Torben Lauesgaard Nissen · Summit, US
Kim Andersen · Ridgewood, US
Christian Hansen · Hannover, DE
Jan Mikkelsen · Copenhagen, DK
Hans Schambye · Copenhagen, DK

Key dates

Filing date	Aug 10, 2006
Grant date	Apr 13, 2010
Priority date	—
Expiry date	Oct 17, 2027

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P37/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.